Skip to the observation
Medicinal BPC

The BPC-157 papers are here for a closer look.

These are the papers and official documents linked in the guide. The notes explain why I’ve used each one and where its answer stops.

What kind of answer can this source give?

I look first for who or what was studied. A rat tendon, a dish of cells and a person reporting less pain can all produce interesting findings. They answer different questions. A confident title doesn’t make those answers interchangeable.

The links below let you go back to the work behind my wording. These notes aren’t scores or a league table of papers. I keep the setting beside the finding so that a useful observation doesn’t quietly turn into a treatment claim.

The cut Achilles tendon experiment

Journal of Orthopaedic Research, 2003

A 2003 rat experiment found stronger tendon repairs with BPC-157 than saline. It wasn’t a human injury study.

Growth hormone receptors in rat tendon cells

Molecules, 2014

Rat Achilles tendon cells made more growth hormone receptors; added hormone encouraged growth. This doesn’t show raised hormone levels in people.

The blood-vessel signal experiments

Journal of Molecular Medicine, 2017

Cells, chick-egg membranes and rats showed effects on blood-vessel growth. Human benefit remains unproven.

The two-person infusion report

Alternative Therapies in Health and Medicine, 2025

Both had tried BPC-157 infusions before, and neither reported a side effect during the two study days. Uncommon risks and long-term safety remain unknown.

Knee pain without a comparison group

Alternative Therapies in Health and Medicine, 2021

Knee-pain treatment records described improvement without a comparison group. They can’t show whether BPC-157 caused it.

Following BPC-157 through rats and dogs

Frontiers in Pharmacology, 2022

BPC-157 broke down rapidly in rats and dogs. That doesn’t supply a human dosing interval.

The FDA’s closer look at BPC-157

FDA advisory committee review, July 2026

The FDA covers identity, human and animal evidence, and safety concerns. Older conference reports appear alongside the published pilots.

The withdrawn nominations and the safety concerns beside them

FDA safety concerns; page marked current April 22, 2026

The page current as of April 22, 2026 lists withdrawn nominations. Taking back a nomination grants no permission to compound the substance.

A review of the distance to human evidence

Current Reviews in Musculoskeletal Medicine, 2025

A 2025 review describes very limited human evidence. It isn’t a new treatment experiment.

BPC-157 in the 2026 sporting rules

World Anti-Doping Agency; 2026 rules took effect on January 1

The 2026 list prohibits BPC-157 at all times. Sport rules answer a separate question from clinical care.

Reading a title
A paper’s wording can be broader than the result its design supports.
Reading a result
The species, comparison and follow-up stay part of the finding.

Back to the research